Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Edwards Lifesciences (NY:EW)

75.06 -0.03 (-0.04%)
Streaming Delayed Price Updated: 3:44 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edwards Lifesciences

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
19 20 Next >
Assessing Edwards Lifesciences: Insights From 11 Financial Analysts
 
Via Benzinga
Jim Cramer: These Airline Stocks 'Trade Wildly,' Edwards Lifesciences 'At The Right Level To Buy'
Cramer likes Delta Air Lines, United Airlines Holdings. "Now, remember, they're very inexpensive stocks, but they trade wildly. But I do like Delta," he added. 
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $16,000 Today
 
Via Benzinga
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
Decoding Edwards Lifesciences's Options Activity: What's the Big Picture?
 
Via Benzinga
Behind the Scenes of Edwards Lifesciences's Latest Options Trends
 
Via Benzinga
EW Stock Earnings: Edwards Lifesciences Beats EPS, Beats Revenue for Q1 2024
EW stock results show that Edwards Lifesciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Edwards Lifesciences Nabs Quarterly Beat And Plans A 'Critical' Spinoff
The company also raised its outlook for the year and now expects 8% to 10% sales growth. 
Via Investor's Business Daily
Edwards Lifesciences Reports First Quarter Results
From Edwards Lifesciences Corporation
Via Business Wire
Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024
From Edwards Lifesciences Corporation
Via Business Wire
The 5 Stocks Most Sold By Insiders This Year
Insiders are selling these 5 stocks increased as their markets advanced, and gains may be capped. Long-term outlooks are positive for growth and share prices. 
Via MarketBeat
$1000 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
How Is The Market Feeling About Edwards Lifesciences?
 
Via Benzinga
What Analysts Are Saying About Edwards Lifesciences Stock
 
Via Benzinga
Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
From Edwards Lifesciences Corporation
Via Business Wire
$100 Invested In Edwards Lifesciences 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
The Latest Analyst Ratings For Edwards Lifesciences
 
Via Benzinga
Edwards Lifesciences Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark
The Relative Strength (RS) Rating for Edwards Lifesciences stock jumped into a new percentile Tuesday, with a rise from 78 to 81. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 15 Years
 
Via Benzinga
What 9 Analyst Ratings Have To Say About Edwards Lifesciences
 
Via Benzinga
Looking Into Edwards Lifesciences's Recent Short Interest
 
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $3,200 Today
 
Via Benzinga
Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR
From Edwards Lifesciences Corporation
Via Business Wire
Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
From Edwards Lifesciences Corporation
Via Business Wire
Here's How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 15 Years
 
Via Benzinga
FDA Advisors Set To Discuss Abbott's TriClip For Heart Valve Disorder As Questions On Pivotal Trial Loom
FDA to review Abbott's TriClip G4 System for severe tricuspid regurgitation. Circulatory System Devices Panel meeting and insights from the briefing document. 
Via Benzinga
Can financial, healthcare, energy stocks rise as rates stay high?
Sectors including financials, healthcare, utilities and energy outperform as interest rates remain high, but some of those industries face challenges in 2024. 
Via MarketBeat
These Analysts Boost Their Forecasts On Edwards Lifesciences Following Q4 Results
Edwards Lifesciences Corporation (NYSE: EW) reported in-line earnings for its fourth quarter on Tuesday. 
Via Benzinga
Edwards Lifesciences Dips On In-Line Profit, Narrow Sales Beat
The company narrowly topped sales expectations and adjusted profit came in line. 
Via Investor's Business Daily
Edwards Lifesciences Reports Fourth Quarter Results
From Edwards Lifesciences Corporation
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.